Skip to main content

Table 5 Continuous T3 and risk of specific prognostic factors in breast cancer in postmenopausal women

From: T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study

Tumour group RR (95% CI) RR* (95% CI) RR** (95% CI)
All 2.87 (1.86-4.43) 2.85 (1.86–4.37) 2.88 (1.90-4.37)
Grade I 2.32 (0.85-6.36) 2.35 (0.82-6.75) 2.37 (0.83-6.77)
Grade II 4.12 (2.19-7.77) 3.99 (2.17-7.36) 3.98 (2.19-7.23)
Grade III 1.18 (0.39-3.55) 1.24 (0.42-3.67) 1.30 (0.45-3.81)
Size ≤20 mm 3.28 (1.86-5.76) 3.31 (1.86-5.89) 3.33 (1.89-5.86)
Size >20 mm 1.64 (0.63-4.26) 1.76 (0.71-4.33) 1.83 (0.76-4.42)
Node positive 3.44 (1.54-7.66) 3.35 (1.59-7.07) 3.37 (1.63-6.96)
Node negative 2.08 (1.05-4.10) 2.08 (1.05-4.10) 2.12 (1.08-4.15)
ER positive 2.44 (1.38-4.32) 2.44 (1.39-4.29) 2.48 (1.43-4.31)
ER negative 4.83 (2.18-10.69) 4.72 (2.16-10.29) 4.69 (2.19-10.06)
PGR positive 2.59 (1.44-4.65) 2.59 (1.45-4.63) 2.62 (1.48-4.63)
PGR negative 3.87 (1.79-8.33) 3.79 (1.81-7.96) 3.81 (1.85-7.84)
  1. RR *adjusted for age, RR **adjusted for age and oral contraceptives.
\